Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 52, Issue 10, Pages 3820-3822Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00361-08
Keywords
-
Categories
Funding
- Targanta Therapeutics
Ask authors/readers for more resources
Oritavancin is a semisynthetic lipoglycopeptide in clinical development for serious gram-positive infections. This study describes the synergistic activity of oritavancin in combination with gentamicin, linezolid, moxifloxacin, or rifampin in time-kill studies against methicillin-susceptible, vancomycin-intermediate, and vancomycin-resistant Staphylococcus aureus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available